Vimian Group (VIMIAN) investor relations material

Executive summary

• Achieved 8% revenue growth to EUR 116.0 million in Q1 2026, with 9% organic growth and double-digit organic growth in three out of four segments.

• Completed three acquisitions year-to-date, expanding into Italy, Denmark, and Ireland, adding up to EUR 11.6 million in annual revenues.

• Strong operational cash conversion above 70% and robust cash flow from operating activities at EUR 23.0 million, up 35% year-over-year.

• Released first CSRD-compliant sustainability report and installed solar panels at a major Italian facility.

• Leadership changes included new Head of MedTech and interim Head of Specialty Pharma.

Financial highlights

• Adjusted EBITDA/EBITA grew 3% to EUR 29.2 million (margin 25.2%), with operating profit up 36% to EUR 21.2 million.

• Profit for the period was EUR 10.1 million, with EPS of EUR 0.02, more than doubling year-over-year.

• Cash flow from operating activities reached EUR 23.0 million, with a cash conversion rate of 73%.

• Net debt rose to EUR 258.4 million, leverage at 2.1x; external lending at EUR 230.2 million.

• Net financial items improved to EUR -3.3 million from EUR -7.5 million year-over-year.

Outlook and guidance

• Expect U.S. Orthopedics to return to organic growth later in spring, with normalization of investment pace in coming quarters.

• Specialty Pharma anticipated to maintain double-digit organic growth for the full year.

• Margin normalization expected in MedTech Orthopedics and Veterinary Services as revenue ramps up, but no significant margin improvement for the full year.

• Continued focus on M&A and organic expansion, including launches in Japan and Portugal in Q3 and ongoing pipeline advancement.

• Limited direct impact anticipated from global geopolitical uncertainties.